HydRx is a vertically-integrated biopharmaceutical Licensed Dealer under the Narcotics Control Regulations of Canada with a focus on developing and commercializing pharmaceutical-grade cannabinoid derivative products. Being one of a limited number of Licensed Dealers in Canada authorized to handle cannabinoid products, HydRx has the ability to wholesale buy process and sell cannabinoid derivatives, from and to Licensed Producers, as well as international markets.
The Company also has a Licensed Producer application entering the Pre-License Inspection stage (the final stage in the licensing process before a Cultivation License is granted).
The HydRx facility is a pharma-grade facility located in the Greater Toronto Area and the company has access to a state-of-the-art R&D laboratory at University Health Network.
The management team and advisory boards have deep experience in the life sciences, drug development, clinical practice and product commercialization processes through their work at top tier organizations including some of the best known Life Sciences companies.
With its patent pending extraction and processing methods HydRx can produce continuous, consistent batch profiles (a key criteria in formulating pharma-grade derivative products). The Company’s products will be dispensed in a range of dosing forms, all providing standard measured doses for reliable and consistent delivery of its therapeutic formulations.